Salmeterol/fluticasone proprionate - Teva Pharmaceutical Industries

Drug Profile

Salmeterol/fluticasone proprionate - Teva Pharmaceutical Industries

Alternative Names: Aerivio Spiromax®; AirDuoTM RespiClick; Fluticasone propionate/salmeterol - Teva; Fluticasone propionate/salmeterol MDI; Fluticasone propionate/salmeterol MDPI; Fluticasone/salmeterol Spiromax® inhalation powder; FS Spiromax; Salmeterol xinafoate/fluticasone propionate - Teva; Salmeterol/fluticasone propionate RespiClick®; Salmeterol/fluticasone propionate Spiromax®

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Teva Pharmaceutical Industries
  • Class Androstadienes; Antiallergics; Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Phenethylamines; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Lipocortin synthesis agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma
  • Registered Chronic obstructive pulmonary disease

Most Recent Events

  • 20 Apr 2017 Launched for Asthma (In adolescents, In adults) in USA (Inhalation) - First global approval
  • 06 Mar 2017 Updated efficacy data from a phase III trial in Asthma presented at the 2017 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI-2017)
  • 30 Jan 2017 Registered for Asthma (In adolescents, In adults) in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top